Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guselkumab - Janssen Biotech

Drug Profile

Guselkumab - Janssen Biotech

Alternative Names: CNTO-1959; TREMFYA; TREMFYA ONE-PRESS

Latest Information Update: 29 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; MorphoSys; Taiho Pharmaceutical
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Preregistration Crohn's disease; Ulcerative colitis
  • Phase III Psoriasis
  • Phase II Giant cell arteritis; Hidradenitis suppurativa; Lupus nephritis; Systemic scleroderma
  • Phase I Familial adenomatous polyposis
  • Discontinued Coeliac disease; Rheumatoid arthritis

Most Recent Events

  • 21 May 2024 Efficacy and adverse events data from a phase IIb trial in Crohn's disease released by Johnson & Johnson
  • 20 May 2024 Efficacy and adverse events data from phase-IIb/III QUASAR trial in Ulcerative colitis released by Johnson & Johnson
  • 01 May 2024 Phase-III clinical trials in Ulcerative colitis (Treatment-experienced) in European Union (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top